Navigation Links
Stopping a deadly killer
Date:3/19/2008

PITTSBURGH, March 19 To develop new strategies to control tuberculosis (TB), a contagious disease that infects one-third of the worlds population and kills almost two million people every year, the University of Pittsburgh Center for Vaccine Research has received an $11.4 million grant from the Bill & Melinda Gates Foundation. The grant will enable Pitt researchers to use new imaging technologies to study TB to shorten and simplify its course of treatment, potentially improving survival and curtailing the global TB epidemic.

One of the most challenging issues in treating TB and stopping its spread is the length of time it takes to adequately stem the infection, said JoAnne Flynn, Ph.D., principal investigator of the grant and professor of microbiology and molecular genetics, University of Pittsburgh School of Medicine. Current drugs are available, but we dont fully understand how or why they work. TB treatment must be continued for at least six months to be effective, placing an undue burden on those who are infected often from the poorest and most disadvantaged countries.

According to Dr. Flynn, TB is difficult to control because the germs that cause the infection hide from the immune system in small tissue nodules called granulomas, enabling the infection to reactivate years, and even decades, later. Although for the most part TB is a curable disease, patients must adhere to treatment long after symptoms have faded. This proves challenging in many regions of the world where medication is not readily accessible. Indeed, an inadequate or incomplete course of treatment is the major factor that causes drug-resistant TB strains to develop. These strains are alarmingly high in many countries around the world.

Current medications for TB were developed more than three decades ago, said Dr. Flynn. To create significantly shorter and simplified approaches to treatment, we must improve our understanding of this disease and how current drugs are localized at the site of infection.

To understand more about the basic biology of TB, Dr. Flynn and colleagues are using the grant to develop positron emission tomography (PET) and computed tomography (CT) imaging studies in non-human primates. By using combined PET/CT, the researchers will be able to follow the progression of the disease in animals over time and analyze changes in tissue and responses to particular drugs. They will be using three imaging technologies radionuclides, fluorescence and mass spectrometry in combination to develop imaging probes and techniques to precisely locate bacteria associated with TB and to explore the underlying factors responsible for slow drug metabolism.

By applying the tools of modern medicine to TB, we hope to lay the groundwork for real-time measurements of TB drug efficacy in clinical trials and develop new targeted therapies that will considerably shorten the length of treatment, said Dr. Flynn.

Tuberculosis is a bacterial disease usually affecting the lungs. Called pulmonary TB, the disease is characterized by a persistent cough, shortness of breath, weight loss and chest pain. Left untreated, one person with active pulmonary TB will infect on average between 10 and 15 other people every year. The bacteria associated with the disease also can infect nearly any part of the body, such as the lymph nodes, the spine or bones. TB is deadly if left untreated.


'/>"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Stopping Statins After Stroke Doubles Death Risk
2. Stopping Tysabri May Worsen MS
3. On 30th Anniversary, Angioplasty Celebrated as Modern Medical Breakthrough in Stopping Heart Attack
4. Hands2GO(R) Hand Sanitizer Offers Alcohol-Free Alternative to Stopping the Spread of Flu at School and Work
5. Common drug for stopping preterm labor may be harmful for babies
6. New Sedona Stopping Diabetes Program
7. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
8. First 90 Days After Stopping Plavix Most Dangerous
9. Physicians focus on stopping pain epidemic
10. Fugitive cancer cells can be blocked by stopping blood cells that aid them
11. Stopping a receptor called nogo boosts the synapses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 13, 2016 , ... In its newly released Infusion Therapy ... should be used to ensure patient safety when placing an IV catheter. A ... the use of vein visualization technology in patients with difficult venous access or ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
(Date:2/12/2016)... PA (PRWEB) , ... February 12, 2016 , ... Each ... event will be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 ... can see new therapy products in action, learn more about their chosen field and ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... at Zuckerberg San Francisco General Hospital on April 5-7. The series is a ... create new habits. The workshops cover a broad range of topics, including coaching ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12 2016  OMS Supply, a ... and medical practitioners, announced today the recent launching of ... visitors a variety of features that enhance the user ... surgery supplies. --> ... a fairly new company that started in early 2016, ...
(Date:2/11/2016)... 2016 - Cardiac Marker ... Medicine and Cancer Therapy. - European Point of ... Markets. - Key Diagnostic Testing Markets. - ... in Genetic Testing. - Molecular Diagnostics in Infectious ... Over-the-Counter Diagnostic Products World Markets. - Point of ...
(Date:2/11/2016)... Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, today announced the submission ... New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, ... (KB0120) of Zimeta for the control of pyrexia (fever) ... --> --> The Chemistry, ...
Breaking Medicine Technology: